<doc>
  <docmeta id="113s2012is">
    <bill congress="113" type="s" number="2012" version="is"/>
    <revision size="16014" annotations="0" status="complete" id="5" commit-time="2014-02-19T18:10:05Z" committer="mbohmer" doc="113s2012is/5.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 S2012 IS: Designer Anabolic Steroid Control Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. Senate</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-02-11</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>S. 2012</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20140211">February 11, 2014</action-date>
			<action-desc>
        <sponsor name-id="S316">Mr. Whitehouse</sponsor> (for himself and <cosponsor name-id="S118">Mr. Hatch</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSJU00">Committee on the Judiciary</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Controlled Substances Act to more effectively regulate anabolic steroids.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one">
			<enum>1.</enum>
			<header>Short
			 title</header>
			<text display-inline="no-display-inline">This Act may be cited as
			 the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Designer Anabolic Steroid Control Act of 2014" proposed="true">Designer Anabolic Steroid Control Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
		</section>
    <section id="ID4d8b70b35a2b4e3f9fee2278066acd3c">
			<enum>2.</enum>
			<header>Amendments to
			 the Controlled Substances Act</header>
			<subsection id="ID29c1ad26f09f4e929e9148f4defffa9e">
				<enum>(a)</enum>
				<header>Definitions</header>
				<text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:102/p:41">Section
			 102(41) of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/802">
            <cato:entity-ref entity-type="uscode" value="usc/21/802//41">21 U.S.C. 802(41)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text>
				<paragraph id="id1CD92EE88F72437E81B1EAA2B4D779DC">
					<enum>(1)</enum>
					<text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph
			 (A)</cato:entity-ref>—</text>
					<subparagraph id="id1037D716322348ECA902AA85B148DC9D">
						<enum>(A)</enum>
						<text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix">clause (xlix)</cato:entity-ref>,
			 by striking <quote>and</quote> at the end;</text>
					</subparagraph>
          <subparagraph id="id7426E0D31D8A496BABEDF42A94C677F5">
						<enum>(B)</enum>
						<text>by redesignating
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlx">clause (xlx)</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:lxxvii" proposed="true">clause (lxxvii)</cato:entity-ref>; and</text>
					</subparagraph>
          <subparagraph id="id23459395833547549A7E71E89A9F7F3B">
						<enum>(C)</enum>
						<text>by inserting
			 after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix">clause (xlix)</cato:entity-ref> the following:</text>
						<quoted-block display-inline="no-display-inline" id="id05865682DAA84881B3F41495FA143A54" style="OLC">
							<clause id="ID9ce4ab538597487e8d9f60c1705008ee">
								<enum>(l)</enum>
								<text>5α-Androstan-3,6,17-trione;</text>
							</clause>
              <clause id="IDd99edfbf65ad4101a70c02c90362d72b">
								<enum>(li)</enum>
								<text>Androst-4-ene-3,6,17-trione;</text>
							</clause>
              <clause id="ID6e37d239b4934677b996a19d21a53623">
								<enum>(lii)</enum>
								<text>Androsta-1,4,6-triene-3,17-dione;</text>
							</clause>
              <clause id="ID6f1d40eeb5e34cc68ea7943539877205">
								<enum>(liii)</enum>
								<text>6-bromo-androstan-3,17-dione;</text>
							</clause>
              <clause id="IDffba6075886c4847bf2aef245894ee64">
								<enum>(liv)</enum>
								<text>6-bromo-androsta-1,4-diene-3,17-dione;</text>
							</clause>
              <clause id="ID8bf975fb66e04ba88847ddfcd722eec3">
								<enum>(lv)</enum>
								<text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
							</clause>
              <clause id="ID1a0ecd58950b4d8aa076b61eb00f3144">
								<enum>(lvi)</enum>
								<text>4-chloro-17α-methyl-androst-4-ene-3β,17β-diol;</text>
							</clause>
              <clause id="IDbc22af6bfc2944b1a1ae3dbe17a22137">
								<enum>(lvii)</enum>
								<text>4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;</text>
							</clause>
              <clause id="IDb471938be5164eb69cd4435dc4dbca97">
								<enum>(lviii)</enum>
								<text>4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;</text>
							</clause>
              <clause id="ID4e3fcc581de54786ace222684ae78c7e">
								<enum>(lix)</enum>
								<text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
							</clause>
              <clause id="ID85c17ce1bd4e44b29cb5eccf670b061c">
								<enum>(lx)</enum>
								<text>2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one;</text>
							</clause>
              <clause id="ID7a1b69be10204fbc950bb07e4d2a9811">
								<enum>(lxi)</enum>
								<text>2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one;</text>
							</clause>
              <clause id="IDa424ad3b0d1a4696a8da83d79e0695f0">
								<enum>(lxii)</enum>
								<text>2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;</text>
							</clause>
              <clause id="IDbb3d65bf884b4695ab0c3d97bcad48fa">
								<enum>(lxiii)</enum>
								<text>[3,2-c]-furazan-5α-androstan-17β-ol;</text>
							</clause>
              <clause id="IDf3cfa2f7220a4aff8677e61fac0b61ab">
								<enum>(lxiv)</enum>
								<text>3β-hydroxy-estra-4,9,11-trien-17-one;</text>
							</clause>
              <clause id="ID95dbf61509234a1cb29d85942a404751">
								<enum>(lxv)</enum>
								<text>17α-methyl-androst-2-ene-3,17β-diol;</text>
							</clause>
              <clause id="ID516cb11bfd28432a803a3d5680b1589a">
								<enum>(lxvi)</enum>
								<text>17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
							</clause>
              <clause id="ID01514efd27bf4b69810769bf3c7a2029">
								<enum>(lxvii)</enum>
								<text>Estra-4,9,11-triene-3,17-dione;</text>
							</clause>
              <clause id="ID56dc7f30212c45009528bf75fbd1fb10">
								<enum>(lxviii)</enum>
								<text>18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one;</text>
							</clause>
              <clause id="IDf445a774eca445bc9e1c823e6a178d33">
								<enum>(lxix)</enum>
								<text>6α-Methyl-androst-4-ene-3,17-dione;</text>
							</clause>
              <clause id="IDb17356b229f44f718e55138adc7a5257">
								<enum>(lxx)</enum>
								<text>17α-Methyl-androstan-3-hydroxyimine-17β-ol;</text>
							</clause>
              <clause id="IDebf89f7823ee4866812a675435ae53ca">
								<enum>(lxxi)</enum>
								<text>17α-Methyl-5α-androstan-17β-ol;</text>
							</clause>
              <clause id="IDdc11b86605b34d9c8aceb60a010b9b64">
								<enum>(lxxii)</enum>
								<text>17β-Hydroxy-androstano[2,3-d]isoxazole;</text>
							</clause>
              <clause id="IDe655d759e9c943ce97dab2654f0c74da">
								<enum>(lxxiii)</enum>
								<text>17β-Hydroxy-androstano[3,2-c]isoxazole;</text>
							</clause>
              <clause id="ID541c733d99e14e3d883ca368d9d138bc">
								<enum>(lxxiv)</enum>
								<text>4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol;</text>
							</clause>
              <clause commented="no" display-inline="no-display-inline" id="ID3b6fe58aac9044fdbb82753cb5f9ad48">
								<enum>(lxxv)</enum>
								<text>[3,2-c]pyrazole-androst-4-en-17β-ol;</text>
							</clause>
              <clause id="IDa953e44e940b45908dfb608f85052b3a">
								<enum>(lxxvi)</enum>
								<text>[3,2-c]pyrazole-5α-androstan-17β-ol;
				and</text>
							</clause>
              <after-quoted-block>;
				and</after-quoted-block>
            </quoted-block>
					</subparagraph>
        </paragraph>
        <paragraph id="id719267FDE06E41DBA79E22FBB6374806">
					<enum>(2)</enum>
					<text>by adding at the
			 end the following:</text>
					<quoted-block display-inline="no-display-inline" id="id2421552BC9D543B1A50C0DF8661CF054" style="OLC">
						<subparagraph id="ID472c9feac40a4a3aa6698ce6d45e1946">
							<enum>(C)</enum>
							<clause commented="no" display-inline="yes-display-inline" id="id1A213D5902BE4B768B5323A92143A5FA">
                <enum>(i)</enum>
								<text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" proposed="true">clause (ii)</cato:entity-ref>
				and the limitations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:6">section 201(i)(6)</cato:entity-ref>, a drug or hormonal
			 substance
				(other than estrogens, progestins, corticosteroids, and
			 de­hy­dro­epi­an­dros­ter­one)
				that is not listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref> and is derived from, or has
			 a chemical
				structure substantially similar to, 1 or more anabolic steroids
			 listed in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref> shall be considered to be an anabolic steroid for
			 purposes of
				this Act if—</text>
								<subclause id="IDd78aeb0ae8a5484d9c82275b39a56d49" indent="up1">
									<enum>(I)</enum>
									<text>the drug or substance has been created or
				manufactured with the intent of producing a drug or other substance
			 that
				either—</text>
									<item id="IDe187bb2316934ffb8065568ee1431975">
										<enum>(aa)</enum>
										<text>promotes muscle growth; or</text>
									</item>
                  <item id="IDcd7e326d99ca441ca2e78cfa5e0e7ef6">
										<enum>(bb)</enum>
										<text>otherwise causes a pharmacological
				effect similar to that of testosterone; or</text>
									</item>
                </subclause>
                <subclause id="ID3e2c87ce61b645be95fe3a5c357c0430" indent="up1">
									<enum>(II)</enum>
									<text>the drug or substance has been, or is
				intended to be, marketed or otherwise promoted in any manner
			 suggesting that
				consuming it will promote muscle growth or any other
			 pharmacological effect
				similar to that of testosterone.</text>
								</subclause>
              </clause>
              <clause id="ID79c4ce7067ec4c7f930ce177ecc1ec43" indent="up1">
								<enum>(ii)</enum>
								<text>A substance shall not be
				considered to be a drug or hormonal substance for purposes of this
			 subparagraph
				if it—</text>
								<subclause id="id7480AB9B57684F1885F225EEDB20D91E">
									<enum>(I)</enum>
									<text>is—</text>
									<item id="id20AD5AF452AB4FAE85738148720DE529">
										<enum>(aa)</enum>
										<text>an herb or other botanical;</text>
									</item>
                  <item id="id71337BD7B78940619528447134484BDB">
										<enum>(bb)</enum>
										<text>a concentrate, metabolite, or extract
				of, or a constituent isolated directly from, an herb or other
			 botanical;
				or</text>
									</item>
                  <item id="idA09CF9B28AB342849ABF6D2F5550C7DF">
										<enum>(cc)</enum>
										<text>a combination of 2 or more substances
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:aa" proposed="true">item (aa)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:bb" proposed="true">(bb)</cato:entity-ref>; and</text>
									</item>
                </subclause>
                <subclause id="id80BAC2AAD38143CC8E83326063F94C9F">
									<enum>(II)</enum>
									<text>is a dietary ingredient for purposes of
				the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/301">
                      <cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et seq</cato:entity-ref>.</external-xref>)</cato:entity>.</text>
								</subclause>
              </clause>
              <clause id="ID43fd1d86f92e4b34a9d82c44d38b09a2" indent="up1">
								<enum>(iii)</enum>
								<text>In accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:515/ss:a">section
				515(a)</cato:entity-ref>, any person claiming the benefit of an exemption or
			 exception under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" proposed="true">clause (ii)</cato:entity-ref> shall bear the burden of going forward with the
			 evidence with
				respect to such exemption or
				exception.</text>
							</clause>
            </subparagraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="ID39d50d6df7aa4c759cfca17865681193">
				<enum>(b)</enum>
				<header>Classification
			 authority</header>
				<text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:201">Section 201 of the Controlled Substances Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/811">21 U.S.C.
			 811</cato:entity-ref>)</cato:entity> is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="id76CFA18EB7D64058AEE6A350FD8C5A93" style="OLC">
					<subsection id="IDdded6bf011f3406e8da62d1250de84c5">
						<enum>(i)</enum>
						<header>Temporary and
				permanent scheduling of recently emerged anabolic steroids</header>
						<paragraph id="ID01774b7c34b647e2ad3e2fc0e875a8f9">
							<enum>(1)</enum>
							<text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney
				General</cato:entity-ref> may issue a temporary order adding a drug or other
			 substance to the
				list of anabolic steroids if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney General</cato:entity-ref> finds that—</text>
							<subparagraph id="ID4016bc0492c3453e9618cba868194156">
								<enum>(A)</enum>
								<text>the drug or other
				substance satisfies the criteria for being considered an anabolic
			 steroid under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41">section 102(41)</cato:entity-ref> but is not listed in that section or by regulation
			 of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney General</cato:entity-ref> as being an anabolic steroid; and</text>
							</subparagraph>
              <subparagraph id="ID161c215fddfd4eb99abbba2fdfc2d054">
								<enum>(B)</enum>
								<text>adding such drug
				or other substance to the list of anabolic steroids will assist in
			 preventing
				the unlawful importation, manufacture, distribution, or dispensing
			 of such drug
				or other substance.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="IDa5f1e619a23544d7a9279e44c1f395b4">
							<enum>(2)</enum>
							<text>An order issued
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall not take effect until 30 days after the
			 date of the
				publication by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney General</cato:entity-ref> of a notice in the Federal
			 Register of the
				intention to issue such order and the grounds upon which such order
			 is to be
				issued. The order shall expire not later than 24 months after the
			 date it
				becomes effective, except that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney General</cato:entity-ref> may, during the
			 pendency of
				proceedings under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:5" proposed="true">paragraph (5)</cato:entity-ref>, extend the temporary scheduling
			 order for up
				to 6 months.</text>
						</paragraph>
            <paragraph id="IDf58b1650a89a4ffbb353070bdc0e54dc">
							<enum>(3)</enum>
							<text>A temporary
				scheduling order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall be vacated upon
			 the issuance
				of a permanent scheduling order under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:5" proposed="true">paragraph (5)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="IDc25fb352a3e442cc9f9211bee06f89cc">
							<enum>(4)</enum>
							<text>An order issued
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> is not subject to judicial review.</text>
						</paragraph>
            <paragraph id="IDb2335198e5b34d64b3dc464e2100ea1b">
							<enum>(5)</enum>
							<text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney
				General</cato:entity-ref> may, by rule, issue a permanent order adding a drug or
			 other substance
				to the list of anabolic steroids if such drug or other substance
			 satisfies the
				criteria for being considered an anabolic steroid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41">section
			 102(41)</cato:entity-ref>. Such
				rulemaking may be commenced simultaneously with the issuance of the
			 temporary
				order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="ID33fb35a38e6a4b1c8eb41805c81b93aa">
							<enum>(6)</enum>
							<text>If a drug or
				other substance has not been temporarily or permanently added to
			 the list of
				anabolic steroids pursuant to this subsection, the drug or other
			 substance
				shall be considered an anabolic steroid if in any criminal, civil,
			 or
				administrative proceeding arising under this Act it has been
			 determined in such
				proceeding, based on evidence presented in the proceeding, that the
			 substance
				satisfies the criteria for being considered an anabolic steroid
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">paragraph
				(41)(A)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:i" proposed="true">(41)(C)(i)</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" proposed="true">(41)(C)(ii) of section
				102</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="ID81b7e644ed024c09827a88338aea3315">
				<enum>(c)</enum>
				<header>Labeling
			 requirements</header>
				<paragraph id="id09207C8FA44145DBB58D440727ED122E">
          <enum>(1)</enum>
          <header>In general</header>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act">Controlled Substances Act</cato:entity-ref> is amended by
			 inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:305">section 305</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/825">
              <cato:entity-ref entity-type="uscode" value="usc/21/825">21 U.S.C. 825</cato:entity-ref>
            </external-xref>)</cato:entity> the following:</text>
					<quoted-block display-inline="no-display-inline" id="id47799CA9C4F04848A5D02C722E4B9E5E" style="OLC">
						<section id="IDdf66ee23f4034f04b094b843dd693fe1">
							<enum>305A.</enum>
							<header>Offenses
				involving false labeling of anabolic steroids</header>
							<subsection id="ID9d6cdef879d74d5ab85719b1627b4511">
								<enum>(a)</enum>
								<header>Unlawful
				acts</header>
								<paragraph id="id56F7403CE8C94FB6A99BBA21E940E275">
									<enum>(1)</enum>
									<text>It shall be
				unlawful—</text>
									<subparagraph id="ID6b32d68bb426428e87d2d8eaf8bfea66">
										<enum>(A)</enum>
										<text>to import into
				the United States or to export from the United States;</text>
									</subparagraph>
                  <subparagraph id="ID2806b00e7dbf423aad1f25eaab59e0f9">
										<enum>(B)</enum>
										<text>to manufacture,
				distribute, dispense, sell, or offer to sell; or</text>
									</subparagraph>
                  <subparagraph id="ID37fdf7c851864f02a741a862ef36e675">
										<enum>(C)</enum>
										<text>to possess with
				intent to manufacture, distribute, dispense, sell, or offer to
			 sell;</text>
									</subparagraph>
                  <continuation-text continuation-text-level="paragraph">any
				anabolic steroid, or any product containing an anabolic steroid,
			 unless it
				bears a label clearly identifying any anabolic steroid contained in
			 such
				steroid or product by the nomenclature used by the International
			 Union of Pure
				and Applied Chemistry (IUPAC).</continuation-text>
                </paragraph>
                <paragraph id="id8DE6F1CDAA2540A781D6654BF91B0D3E">
									<enum>(2)</enum>
									<text>A product that is
				the subject of an approved application as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section
			 505(b)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">(i)</cato:entity-ref> or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">(j) of the Federal Food, Drug, and Cosmetic Act (</cato:entity-ref>
                    <external-xref legal-doc="usc" parsable-cite="usc/21/355">
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/b">21 U.S.C. 355(b)</cato:entity-ref>
                    </external-xref>,
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/i">(i)</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/j">(j)</cato:entity-ref>)
				is exempt from the International Union of Pure and Applied
			 Chemistry
				nomenclature requirement of this subsection if such product is
			 labeled in the
				manner required by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref>.</text>
								</paragraph>
              </subsection>
              <subsection id="ID6c621c7feff841e4b74be5793fda0187">
								<enum>(b)</enum>
								<header>Criminal
				penalties</header>
								<text>Any person who violates <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305A/ss:a" proposed="true">subsection (a)</cato:entity-ref> knowing,
				intending, or having reasonable cause to believe, that the
			 substance or product
				is an anabolic steroid, or contains an anabolic steroid, shall be
			 sentenced to
				a term of imprisonment of not more than 10 years, a fine not to
			 exceed the
				greater of that authorized in accordance with the provisions of
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18">title 18,
				United States Code</cato:entity-ref>, or $500,000 if the defendant is an individual
			 or $2,500,000
				if the defendant is other than an individual, or both.</text>
							</subsection>
              <subsection id="ID55c50b6d1adc47f7875803b67a88eb2b">
								<enum>(c)</enum>
								<header>Civil
				penalties</header>
								<paragraph id="IDb0645806f1dc49bfb89cfc5274e43b7b">
									<enum>(1)</enum>
									<text>Any person who
				violates <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305A/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be subject to a civil penalty as
			 follows:</text>
									<subparagraph id="ID89cbaf9d8f8f434eaa880d84defd7fe1">
										<enum>(A)</enum>
										<text>In the case of an
				importer, exporter, manufacturer, or distributor (other than as
			 provided in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305A/ss:c/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>), up to $500,000 per violation. For purposes of
			 this
				subparagraph, a violation is defined as each instance of
			 importation,
				exportation, manufacturing, or distribution, and each anabolic
			 steroid or
				product imported, exported, manufactured, or distributed.</text>
									</subparagraph>
                  <subparagraph id="ID69837698f0634e58a41a9f8977cef817">
										<enum>(B)</enum>
										<text>In the case of a
				sale or offer to sell at retail, up to $25,000 per violation. For
			 purposes of
				this subparagraph, each sale and each product offered for sale
			 shall be
				considered a separate violation. Continued offers to sell by a
			 person 10 or
				more days after written notice (including through electronic
			 message) to the
				person by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney General</cato:entity-ref> or the Secretary shall be considered
			 additional
				violations.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="IDdad9decc59e54be6a82c7ef6adb6ee66">
									<enum>(2)</enum>
									<text>In this
				subsection, the term <term>product</term> means a discrete article, either in
				bulk or in finished form prepared for sale. A number of articles,
			 if similarly
				packaged and bearing identical labels, shall be considered as one
			 product, but
				each package size, form, or differently labeled article shall be
			 considered a
				separate product.</text>
								</paragraph>
              </subsection>
              <subsection id="ID81c893c1cd7a4af8b2b0b7ebbe0785b6">
								<enum>(d)</enum>
								<header>Identification
				and publication of list of products containing anabolic steroids</header>
								<paragraph id="ID26f3d665b95e498885724fe124b48827">
									<enum>(1)</enum>
									<text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney
				General</cato:entity-ref> may, in his discretion, collect data and analyze products
			 to determine
				whether they contain anabolic steroids and are properly labeled in
			 accordance
				with this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney General</cato:entity-ref> may publish in the Federal
			 Register or
				on the website of the Drug Enforcement Administration a list of
			 products that
				he has determined, based on substantial evidence, contain an
			 anabolic steroid
				and are not labeled in accordance with this section.</text>
								</paragraph>
                <paragraph id="IDe08d943811914f5da34fdf1613fc65f7">
									<enum>(2)</enum>
									<text>The absence of a
				product from the list referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:305A/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall not
			 constitute
				evidence that the product does not contain an anabolic
				steroid.</text>
								</paragraph>
              </subsection>
            </section>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
        <paragraph id="id72A48FDFA5BC4089BBC13C341CB13CDA">
          <enum>(2)</enum>
          <header>Table of contents</header>
          <text>The table of contents for the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970">Comprehensive Drug Abuse Prevention and Control Act of 1970</cato:entity-ref> is
			 amended by inserting after the item relating to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970/s:305">section 305</cato:entity-ref> the following:</text>
          <quoted-block display-inline="no-display-inline" id="idDDD7BC585CEF4E2FA98792BD7CB6D99C" style="OLC">
            <toc>
              <toc-entry bold="off" level="section">Sec. 305A. Offenses involving false labeling of anabolic steroids.</toc-entry>
            </toc>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
    </section>
    <section id="ID49693ef136bf4bc49395119920cc5085">
			<enum>3.</enum>
			<header>Sentencing
			 commission guidelines</header>
			<text display-inline="no-display-inline">The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1030">United States Sentencing Commission</cato:entity-ref> shall—</text>
			<paragraph id="IDeb207ebd53644815956128c42c744ffb">
				<enum>(1)</enum>
				<text>review and amend
			 the Federal sentencing guidelines with respect to offenses involving
			 anabolic
			 steroids, including the offenses under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970/s:305A" proposed="true">section 305A</cato:entity-ref> of
			 the
			 Controlled Substance Act, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Designer Anabolic Steroid Control Act of 2014/s:2" proposed="true">section 2</cato:entity-ref>;</text>
			</paragraph>
      <paragraph id="ID1cf0487995a84cf8a24faa996fe31fce">
				<enum>(2)</enum>
				<text>amend the Federal
			 sentencing guidelines, including notes to the drug quantity tables, to
			 provide
			 clearly that in a case involving an anabolic steroid not in a tablet,
			 capsule,
			 liquid, or other form where dosage can be readily ascertained (such as a
			 powder, topical cream, gel, or aerosol), the sentence shall be determined
			 based
			 on the entire weight of the mixture or substance;</text>
			</paragraph>
      <paragraph id="ID49ee3e905d064190bfaf3e3485b9d19e">
				<enum>(3)</enum>
				<text>amend the
			 applicable guidelines by designating quantities of mixture or substance
			 that
			 correspond to a unit so that offenses involving such forms of anabolic
			 steroids
			 are penalized at least as severely as offenses involving forms whose
			 dosage can
			 be readily ascertained; and</text>
			</paragraph>
      <paragraph id="IDc8ec5d6d82c94eefa55ba25cb79b2a3e">
				<enum>(4)</enum>
				<text>take such other
			 action as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1030">Commission</cato:entity-ref> considers necessary to carry out this Act and
			 this
			 section.</text>
			</paragraph>
    </section>
    <section id="idE15B942CA68A4A63B0CC2334506E7E00">
			<enum>4.</enum>
			<header>Congressional
			 oversight</header>
			<text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1524">Administrator of
			 the Drug Enforcement Administration</cato:entity-ref> shall report to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> every 2
			 years—</text>
			<paragraph id="idB6ECB5564E374F10B23A7D9184D3FCF5">
				<enum>(1)</enum>
				<text>what anabolic
			 steroids have been scheduled on a temporary basis under the provisions of
			 this
			 Act; and</text>
			</paragraph>
      <paragraph id="id14CB5F2BB2F14CDBA154205FB20A9B91">
				<enum>(2)</enum>
				<text>the findings and
			 conclusions that led to such scheduling.</text>
			</paragraph>
    </section>
  </legis-body>
</bill>
</doc>